NSWRC(SH:600165)2018-04-27 16:00Financial Performance - Operating revenue fell by 31.27% to CNY 162,706,678.56 year-on-year[6] - Net profit attributable to shareholders decreased by 69.34% to CNY 485,586.09 compared to the same period last year[6] - Basic earnings per share dropped by 69.57% to CNY 0.0007[6] - The company reported a significant reduction in sales expenses by 88.16% to ¥3,576,512.64, due to the absence of metal products and stem cell business[14] - Net profit decreased by 69.20% to ¥1,213,333.77, attributed to the lack of stem cell business[14] - The company reported an operating loss of ¥503,831.00, compared to an operating profit of ¥1,695,003.84 in the previous period[36] - The total comprehensive income for the current period is ¥1,213,333.77, compared to ¥3,939,295.95 in the previous period, reflecting a decline of 69.1%[37] Cash Flow - Net cash flow from operating activities was negative at CNY -7,240,430.46, a decline of 199.76% year-on-year[6] - Cash flow from operating activities turned negative at -¥7,240,430.46, a decrease of 199.76% compared to the previous period[17] - Total cash outflow from operating activities rose to ¥255,847,430.25 from ¥249,385,263.05, an increase of about 2.9%[44] - The cash flow from operating activities net amount was negative, highlighting potential operational challenges moving forward[44] - The ending cash and cash equivalents balance dropped to ¥35,790,258.18 from ¥96,204,835.02, a decrease of approximately 62.8%[45] Assets and Liabilities - Total assets decreased by 8.61% to CNY 2,101,064,082.16 compared to the end of the previous year[6] - Current assets decreased from ¥1,539,368,306.03 to ¥1,333,485,195.75, representing a reduction of about 13.4%[25] - Total liabilities decreased from ¥1,278,827,607.29 to ¥1,079,751,690.69, a decline of about 15.6%[27] - Current liabilities decreased from ¥1,278,130,536.73 to ¥1,079,072,225.75, representing a reduction of approximately 15.6%[26] - Owner's equity increased slightly from ¥1,020,216,356.55 to ¥1,021,312,391.47, a growth of about 0.1%[27] Investments - Investment cash flow decreased significantly by 540.88% to -¥19,985,410.43, mainly due to increased investment in the lauric acid project[17] - The company plans to acquire 90% of the equity in Shanxi Huangcheng Xiangfu Aerospace Automobile Manufacturing Co., Ltd. for approximately ¥800 million[20] - The company is actively pursuing the implementation of the acquisition agreement for 80% equity of Boya Stem Cell Technology Co., Ltd. to mitigate investment risks[19] - The company has received a total of ¥500 million in performance guarantee deposits related to the acquisition of Boya Stem Cell[19] Shareholder Information - The total number of shareholders at the end of the reporting period was 15,341[9] - The largest shareholder, Shanghai Zhongneng Enterprise Development (Group) Co., Ltd., held 200,000,000 shares, accounting for 29.20% of total shares[9] Other Financial Metrics - The weighted average return on net assets decreased by 0.14 percentage points to 0.0563%[6] - The company reported a significant increase in non-recurring losses, with a total of CNY 1,195,804.18 after tax adjustments[8] - Cash and cash equivalents decreased by 58.51% to ¥130,456,658.18 from the beginning of the year[12] - Accounts receivable decreased by 65.40% to ¥2,516,942.80, primarily due to payment of goods[13] - Total operating costs amount to ¥169,233,671.93, down 29.8% from ¥241,115,530.55 in the previous period[36] - Financial expenses were ¥8,289,032.22, down from ¥27,344,685.99, indicating a decrease of 69.7%[36]